Internet searches can identify drug safety issues well ahead of public alerts

The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010. The researchers developed automated tools to analyse the queries of people who searched for information on the antidepressant (paroxetine) and a cholesterol lowering drug (pravastatin), using the search engines Google, Bing and Yahoo.

In 2010, it was not yet public knowledge that taking both these two drugs caused high blood sugar (hyperglycaemia), but the authors later extracted this information by mining the US drugs regulator's medicines side effect reporting system (AERS) and confirming the finding in a separate laboratory study.

In the web log study, the authors looked at whether people who had searched online for either one of the drugs separately, or for both of them, would also search with queries containing terms associated with the symptoms of high blood sugar.

In all, they analysed 82 million drug, symptom, and condition queries from among 6 million web users.

They found that online searches for information on prescription drugs was common, with more than one in 250 people looking up at least one of the 100 top selling drugs in the US, including paroxetine and pravastatin.

For people who searched online for both drugs during the 12 month period, queries were made on the same day in almost a third (29.61%) of searches, while four out of 10 were in the same week. Six out of 10 were made within the same month.

During the study period, those people who looked up both drugs online were almost twice as likely to search for terms associated with high blood sugar as were those who looked up the drugs separately.

One in 10 of those looking up both drugs did this, compared with around one in 20 of those looking up each drug separately. Just 0.3% of all users searched for one or more terms associated with high blood sugar over the 12 months.

These differences in search patterns were evident across the whole period of the study, and were not influenced by public information as the discovery of the interaction between this particular pair of drugs was only made in 2011.

Analysis of other 31 drug pair interactions associated with high blood sugar also indicated similar patterns, suggesting that the value of log analysis is not just confined to paroxetine and pravastatin.

"There is a potential public health benefit in listening to such signals, and integrating them with other sources of information," write the authors. "We see a potentially valuable signal, even though search logs are unstructured, not necessarily related to health, and can include any words entered by users," they add.

And they conclude: "We believe that patient search behaviour directly captures aspects of patients' concerns about sensed [symptoms] and can complement more traditional sources of data for pharmacovigilance [drug safety monitoring]."

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Bristol-Myers Squibb announces immunotherapy clini…

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squi...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Novo Nordisk and Glooko partner to develop digital…

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabet...

Read more

FDA grants Roche's cancer immunotherapy TECENTRIQ …

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA)...

Read more

AstraZeneca and Lilly to develop second potentiall…

AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]